Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of AML

Dr Eirini Papapetrou - Icahn School of Medicine at Mount Sinai, New York, USA
Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of AML ( Dr Eirini Papapetrou - Icahn School of Medicine at Mount Sinai, New York, USA )
28 Apr 2023

Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC

Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRC ( Dr Jamal Zekri - King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia )
27 Apr 2023

Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death

Dr Joshua Choe - Columbia University, New York City, USA
Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death ( Dr Joshua Choe - Columbia University, New York City, USA )
27 Apr 2023

Breast and emerging indications for IORT

Dr David Martinez Perez - AUNA, Lima, Peru
Breast and emerging indications for IORT ( Dr David Martinez Perez - AUNA, Lima, Peru )
26 Apr 2023

The advantages of IORT for early breast cancer treatment

Dr David Martinez Perez - AUNA, Lima, Peru
The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )
26 Apr 2023

Encouraging safety and efficacy for REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with RRMM

Dr Attaya Suvannasankha - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA
Encouraging safety and efficacy for REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with RRMM ( Dr Attaya Suvannasankha - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )
20 Apr 2023

ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC

Dr Samer Srour - The University of Texas MD Anderson Cancer Center, Houston, USA
ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC ( Dr Samer Srour - The University of Texas MD Anderson Cancer Center, Houston, USA )
20 Apr 2023

Atezo plus bev demonstrates efficacy in preventing recurrence in patients with high-risk HCC

Prof Pierce Chow - Duke-NUS Medical School, Singapore
Atezo plus bev demonstrates efficacy in preventing recurrence in patients with high-risk HCC ( Prof Pierce Chow - Duke-NUS Medical School, Singapore )
20 Apr 2023

IO-108 shows promising results in the treatment of advanced relapsed or refractory solid tumours

Dr Matthew Taylor - Providence Cancer Institute, Portland, USA
IO-108 shows promising results in the treatment of advanced relapsed or refractory solid tumours ( Dr Matthew Taylor - Providence Cancer Institute, Portland, USA )
20 Apr 2023

MatchMiner: An open-source AI precision medicine trial matching platform

Dr Harry Klein - Dana Farber Cancer Institute, Boston, USA
MatchMiner: An open-source AI precision medicine trial matching platform ( Dr Harry Klein - Dana Farber Cancer Institute, Boston, USA )
20 Apr 2023

Indications for the appropriate use of a PET-CT scan for common cancers

Dr Jonas Santiago - St Luke's Medical Center, Manila, Philippines
Indications for the appropriate use of a PET-CT scan for common cancers ( Dr Jonas Santiago - St Luke's Medical Center, Manila, Philippines )
19 Apr 2023

Choosing Wisely in neoadjuvant treatment for different cancers in the Philippines

Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines
Choosing Wisely in neoadjuvant treatment for different cancers in the Philippines ( Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines )
19 Apr 2023